Wedbush maintains Outperform rating on Adicet Bio, $28 price target

Wedbush maintained their Outperform rating on Adicet Bio's stock with a price target of $28.00.The price target implies an upside of 340.9% from the Sep 28 close of $6.35.Key takeaways from the analyst noteStrong Clinical Data and FDA Alignment: Adicet Bio has demonstrated compelling clinical data…